A new brain implant that can record neural activity while it simultaneously delivers electric current has been implanted into a patient for the first time. The new device from Medtronic, a Minneapolis-based medical device company, can also adjust its electrical output in response to the changing conditions of the brain.
The battle over Medtronic's Infuse bone-growth protein continues to be a roller-coaster, with judges in 2 states issuing seemingly conflicting rulings about the validity of patient injury lawsuits against the Minnesota medical device giant and its troubled Infuse bone-growth protein.
Medtronic, one of the world’s largest medical technology companies, has entered into an innovative partnership with The Johns Hopkins University, agreeing to provide $200,000 a year for up to three years and skilled mentoring to help biomedical engineering students design new healthcare solutions for underserved patients in developing countries.
Edwards Lifesciences wants a federal judge to rule that a pair of patents owned by arch-rival Medtronic are invalid because they aren't specific enough. The patents cover nerve stimulation technology. Edwards and Medtronic have spent considerable time in courts around the world, each arguing that the other's transcatheter aortic valve implant infringes various patents.
The FDA put its highest-risk label, Class I, on a recall of Medtronic's (NYSE:MDT) Paradigm insulin infusion pumps, which the medtech giant had warned about earlier this year. Medtronic Canada said last month that it received 2 reports on its Paradigm and Polyfin infusion devices, concerning the over- and under-delivery of insulin therapy.
Medtronic (NYSE:MDT) prevailed in an antitrust lawsuit filed over a bone mill made by Lenox MacLaren Surgical, with a federal judge ruling that Lenox misrepresented the size of the bone mill market and failed to adequately market its own device.
Some 55 U.S. hospitals agreed to pay a total of $34 million to settle U.S. Justice Dept. charges that they overcharged Medicare for Medtronic's (NYSE:MDT)'s kyphoplasty spine procedure, acquired in the $3.9 billion buyout of Kyphon in 2007, the Justice Dept. said today.
Minnesota medical device giant Medtronic (NYSE:MDT) confirmed today that it recalled certain of its already-troubled Infuse spinal fusion surgery kits after learning of possible contamination in sponges manufactured by Integra Lifesciences.
In June 2013, Medtronic, Inc. (NYSE: MDT) initiated four medical device notifications to customers worldwide about the SynchroMed® Implantable Infusion System. These notifications provide clinicians with information to help identify and manage issues that impact the safe and reliable delivery of therapy using the SynchroMed Implantable Infusion System.
In November 2012 and February 2013, Andrew Johnson underwent a surgical procedure, Deep Brain Stimulation surgery, to help control his motor symptoms. This video represents his experience of how DBS has helped him. He is using a device from Medtronic.
Doctors are reporting a major step toward an "artificial pancreas," a device that would constantly monitor blood sugar in people with diabetes and automatically supply insulin as needed. A key component of such a system—an insulin pump programmed to shut down if blood-sugar dips too low while people are sleeping—worked as intended in a three-month study of 247 patients.
ALRT's Internet-Based Glucose Monitoring Platform Compares Favorably with Medtronic's Continuous Glucose Monitoring SystemJune 24, 2013 8:18 am | by The Associated Press | News | Comments
This weekend, ALR Technologies announced at the American Diabetes Association meeting in Chicago that the A1c reduction in insulin-requiring patients with type 2 diabetes mellitus who managed their blood glucose using ALRT's Internet-Based Glucose Monitoring (IBGMS) platform, "Health-e-Connect", demonstrated comparable results to patients using Medtronic's "Guardian REAL-Time Continuous Glucose Monitoring System" (RT-CGM).
Shares of Medtronic slipped Tuesday, a day after the medical device maker announced findings from independent reviews of studies of its Infuse bone graft. The Minneapolis company said the reviews, conducted through Yale University, concluded that clinical success rates with its Infuse product were equivalent to more traditional bone graft procedures in which bone is taken from the hip.
Medtronic Announces CE Mark of Its ReDuX(TM) Plier Instrument, an Innovative Device to Perform Osteotomies in Spinal Deformity SurgeriesJune 13, 2013 2:06 am | by The Associated Press | News | Comments
Medtronic, Inc. has announced the CE Mark and the European launch of the ReDuX Plier, a new instrument specially designed for use during osteotomies. With the launch of this first specially-designed surgical instrument in the spinal orthopaedic industry, physicians in the European community may now perform a more controlled osteotomy closure for people with a severe form of spinal curvature.
Continuing to demonstrate its ongoing commitment to advancing interventional treatments of peripheral artery disease and the evidence to support their adoption, Medtronic, Inc. announced today that enough patients have been enrolled in its clinical studies of the IN.PACT Admiral drug-eluting balloon to support the company's U.S. regulatory approval submission of the novel angioplasty device.
The Endurant AAA stent graft system from Medtronic, Inc. continues to distinguish itself, with new data on the market-leading device for the endovascular repair of abdominal aortic aneurysms demonstrating durable clinical performance through three years of patient follow-up.
Medtronic, Inc. (NYSE: MDT) is expanding its market-leading portfolio of products for endovascular aortic repair in the United States with two new medical devices: the company recently received approval from the U.S. Food and Drug Administration (FDA) for the Endurant II Aorto-Uni-Iliac (AUI) Stent Graft System and the FDA’s 510(k) clearance for the Sentrant Introducer Sheath.
Medtronic Completes Enrollment in Landmark U.S. Study of Symplicity Renal Denervation System for Treatment-Resistant HypertensionMay 23, 2013 6:06 am | by The Associated Press | News | Comments
Medtronic, Inc., today announced it has finished randomizing Symplicity HTN-3, the company's pivotal U.S. clinical trial of the Symplicity renal denervation system for treatment-resistant hypertension. Renal denervation is a minimally invasive, catheter-based procedure to reduce activity of the renal (kidney) nerves, which are part of the sympathetic nervous system and help regulate blood pressure.
Medtronic Finds TAVI with CoreValve System Cost Effective for Treating Patients with Severe Aortic StenosisMay 21, 2013 4:06 am | by The Associated Press | News | Comments
Focused on offering devices that provide both clinical and economic value, Medtronic, Inc. unveiled the results of a cost-effectiveness model comparing transcatheter aortic valve implantation with the CoreValve System to medical management. Presented at EuroPCR 2013, the United Kingdom-based analysis compared the "real world" Medtronic CoreValve ADVANCE study to the medical management cohort of the PARTNER B study.
Expanding its portfolio of medical technology for the interventional treatment of cardiovascular disease, Medtronic, Inc. (NYSE: MDT) announced today that the Export Advance aspiration catheter recently received the CE (Conformité Européenne) mark and will soon be launched in Europe and other international markets.
Medtronic has announced new data demonstrating that simultaneously pacing the lower chambers of the heart, or biventricular (BiV) pacing with a cardiac resynchronization therapy (CRT) device, significantly improves heart failure symptoms and quality of life in a subset of heart failure patients.
Data Show Medtronic-Exclusive LIA Software Detects Non-Medtronic Lead Issues at a Greater Rate Than Standard Impedance MonitoringMay 10, 2013 4:06 pm | by The Associated Press | News | Comments
MINNEAPOLIS and DENVER - May 10, 2013 - Data presented today at Heart Rhythm 2013, the Heart Rhythm Society's 34th Annual Scientific Sessions, show that Medtronic, Inc. (NYSE:MDT) Lead Integrity Alert (LIA) software detected pace/sense lead issues in non-Medtronic leads at a...
Medtronic's current internal analysis and testing shows iPad technology presents no risk of electromagnetic interference with Medtronic implantable cardiac rhythm devices when used per manufacturer's instructions. However, as a precaution, patients implanted with a pacemaker or ICD are advised to follow Apple and Medtronic labeling recommendations and maintain a distance of six inches between the iPad and implanted device.
Gain best practices in overcoming international labeling challenges at the Medical Device Global Labeling Strategies Conference, July 24-25, 2013 in Minneapolis, MN. This premier marcus evans event will bring together leading medical device labeling professionals to discuss how to successfully create a label on both a national and international scale.
Medtronic Announces FDA Approval of New Portfolio Of Next-Gen Cardiac Resynchronization Therapy Devices, Implantable Cardioverter-DefibrillatorsMay 6, 2013 10:18 am | by Medtronic | News | Comments
Medtronic, Inc. has announced U.S. Food and Drug Administration (FDA) approval and U.S. launch of its newest cardiac devices: the Viva® portfolio of cardiac resynchronization therapy with defibrillation (CRT-D) devices, and the Evera® portfolio of implantable cardioverter-defibrillators (ICD).